Physician profile
Brett J Meyer
NPI 1114140803
$7,863.40
in general payments reported to CMS, 2019-2025
44 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $727 · 2021: $1,177 · 2022: $1,064 · 2023: $1,030 · 2024: $1,176 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,543.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,329.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,294.42 | 2021-2025 | |
| Amgen INC. | $1,163.57 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $565.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $384.92 | 2019-2025 | |
| Allergan, INC. | $338.79 | 2019-2020 | |
| Lilly USA, LLC | $325.42 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $323.32 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $164.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $158.83 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.37 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $145.39 | 2019-2025 | Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $133.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.28 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $117.18 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.